History of Milmed
Research into the positive impact of electromagnetic millimeter waves on biological objects has been going on for many decades. It has mainly been about influencing the objects from the outside, our pharmabiotic, (LBP-Live Biotherapeutic Products), treats from the inside.
A major step forward was taken when a suspension containing treated yeast cells was developed. Although the manufacturing process was complicated and the shelf life very short, it provided great opportunities for further research. The suspension was named Milmed, and the unique properties of the product was originated from the electromagnetic millimeter wave treated strain of yeast cells.
Case studies began in 2007 but the real work started when Professor Trevor Archer joined the existing team. He led 7 in vivo studies within a Parkinson’s model between the years 2008-2013 at Uppsala University.
The results of these studies formed the basis for the first patent application in the product's history, a patent for the treatment of neurodegenerative diseases that was approved back in 2011.
Research in the form of preclinical trials continued at a steady pace to further to strengthen the product's legitimacy. Another imperative step was taken when a collaboration with Europe's largest university in Sapienza, Rome, began in 2016. Professor Rita Businaro is still, at present, leading our research work regarding in vitro studies. The primary priority in Sapienza was a toxicity-study to prove that our LBP is completely free of toxins. This was carried out in 2017 and it turned out that Milmed does not contain any toxins at all. In the summer of 2018, our current CEO negotiated an agreement where all intellectual property rights were transferred to his company. The agreement also contained a clause which means that the old company has no future financial claims or rights to royalties or the like. Several human studies were conducted after we discovered clear indications that Milmed relieves or removes allergic symptoms. In these studies, the focus was primarily set on pollen, grass and fur allergies. The results were very satisfying, and a subsequent patent application was approved in October 2020.
An extended research agreement with Sapienza University was signed in April 2019 where indications of a new treatment area, inflammatory diseases, was studied. The positive results of these studies led the company to apply for a new patent, filed in June 2021. The company received a PCT approval for treatment of inflammatory diseases in September of 2022. The work continues towards becoming an approved medicinal pharmabiotic and synopsis for future clinical trials is ready. Milmed has never been licensed to a third parti.
An important priority for Milmed Unico AB from the start has been to be able to produce the product in a dry form. This process was initiated in 2014 and after several years of research and testing of the dry product, it was finalized in collaboration with Sapienza University and Orkla Group in April 2021. This is crucial for future development and the possibility to take the product to market. Milmed is now a stand-alone pharmabiotic product with a promising future and the product has already change many Milmed-users’ lives in a positive way.